WO2005051980A1 - Depeptidized inhibitors of hepatitis c virus ns3 protease - Google Patents
Depeptidized inhibitors of hepatitis c virus ns3 protease Download PDFInfo
- Publication number
- WO2005051980A1 WO2005051980A1 PCT/US2004/039131 US2004039131W WO2005051980A1 WO 2005051980 A1 WO2005051980 A1 WO 2005051980A1 US 2004039131 W US2004039131 W US 2004039131W WO 2005051980 A1 WO2005051980 A1 WO 2005051980A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- group
- pharmaceutical composition
- alkyl
- aryl
- Prior art date
Links
- 0 CC(**NC(*)C(NC(*)C(N(C[C@@](C1)OI)[C@@]1C(NC1(C(*)C1)C(*)=O)=O)=O)=O)=O Chemical compound CC(**NC(*)C(NC(*)C(N(C[C@@](C1)OI)[C@@]1C(NC1(C(*)C1)C(*)=O)=O)=O)=O)=O 0.000 description 14
- BYDLPLSQNDYWMI-UHFFFAOYSA-N CC(C)Nc1nc(-c2nc3cc(OC)ccc3c(O)c2)c[s]1 Chemical compound CC(C)Nc1nc(-c2nc3cc(OC)ccc3c(O)c2)c[s]1 BYDLPLSQNDYWMI-UHFFFAOYSA-N 0.000 description 10
- KGLWTKFQMVBRQF-UHFFFAOYSA-N CC(C)(C)S(CC1(CCCCC1)C(OC)=O)(=O)=O Chemical compound CC(C)(C)S(CC1(CCCCC1)C(OC)=O)(=O)=O KGLWTKFQMVBRQF-UHFFFAOYSA-N 0.000 description 2
- BFBYIHQRQKPPHG-PKHNTBLGSA-N CC(C)(C)C(CN(C(c1c2cccc1)=O)C2=O)NC(N[C@@H](CCCCC/C=C\C(C1)[C@]1(C(O)=O)NC([C@H]1N2CCC1)=O)C2=O)=O Chemical compound CC(C)(C)C(CN(C(c1c2cccc1)=O)C2=O)NC(N[C@@H](CCCCC/C=C\C(C1)[C@]1(C(O)=O)NC([C@H]1N2CCC1)=O)C2=O)=O BFBYIHQRQKPPHG-PKHNTBLGSA-N 0.000 description 1
- NYIXKPHWWHEFOQ-UYTSJBBESA-N CC(C)(C)C(CN(C)S(C)(=O)=O)NC(N[C@@H](CCCCCCCC(C1)[C@]1(C(O)=O)NC([C@H]1N2CCC1)O)C2=O)=O Chemical compound CC(C)(C)C(CN(C)S(C)(=O)=O)NC(N[C@@H](CCCCCCCC(C1)[C@]1(C(O)=O)NC([C@H]1N2CCC1)O)C2=O)=O NYIXKPHWWHEFOQ-UYTSJBBESA-N 0.000 description 1
- WIGNSFUAOOHMJN-GPYNLPIZSA-N CC(C)(C)C(CN(C)S(N(C)C)(=O)=O)NC(N[C@@H](CCCCC/C=C\C(C1)[C@]1(C(O)=O)NC([C@H]1N2CCC1)=O)C2=O)=O Chemical compound CC(C)(C)C(CN(C)S(N(C)C)(=O)=O)NC(N[C@@H](CCCCC/C=C\C(C1)[C@]1(C(O)=O)NC([C@H]1N2CCC1)=O)C2=O)=O WIGNSFUAOOHMJN-GPYNLPIZSA-N 0.000 description 1
- RRQMWADMXFOYTO-ACTGWOQYSA-N CC(C)(C)C(CN(CCCN1C)S1(=O)=O)OC(N[C@@H](CCCCC/C=C\C(C1)[C@]1(C(O)=O)NC([C@H]1N2CCC1)=O)C2=O)=O Chemical compound CC(C)(C)C(CN(CCCN1C)S1(=O)=O)OC(N[C@@H](CCCCC/C=C\C(C1)[C@]1(C(O)=O)NC([C@H]1N2CCC1)=O)C2=O)=O RRQMWADMXFOYTO-ACTGWOQYSA-N 0.000 description 1
- BVYSDUQPEHINHL-DXSVTDEJSA-N CC(C)(C)C(CN(CCN1C)S1(=O)=O)OC(N[C@@H](CCCCC/C=C\C(C1)[C@]1(C(O)=O)NC([C@H]1N2CCC1)=O)C2=O)=O Chemical compound CC(C)(C)C(CN(CCN1C)S1(=O)=O)OC(N[C@@H](CCCCC/C=C\C(C1)[C@]1(C(O)=O)NC([C@H]1N2CCC1)=O)C2=O)=O BVYSDUQPEHINHL-DXSVTDEJSA-N 0.000 description 1
- FEYOJASIFYRAMM-HEZDXAQVSA-N CC(C)(C)C(CN(Cc1c2cccc1)S2(=O)=O)NC(N[C@@H](CCCCC/C=C\C(C1)[C@]1(C(O)=O)N1)COCN(CCC2)[C@@H]2C1=O)=O Chemical compound CC(C)(C)C(CN(Cc1c2cccc1)S2(=O)=O)NC(N[C@@H](CCCCC/C=C\C(C1)[C@]1(C(O)=O)N1)COCN(CCC2)[C@@H]2C1=O)=O FEYOJASIFYRAMM-HEZDXAQVSA-N 0.000 description 1
- CGSLOQAKUSYPLZ-SKQVRNOWSA-N CC(C)(C)S(CC1(CCCCC1)NC(N[C@@H](C(C1)C1CC/C=C\C[C@@H](C(OC)=O)NC([C@H](C1)N2C[C@@H]1Oc1c(ccc(OC)c3)c3nc(C(OC)=O)c1)=O)C2=O)=O)(=O)=O Chemical compound CC(C)(C)S(CC1(CCCCC1)NC(N[C@@H](C(C1)C1CC/C=C\C[C@@H](C(OC)=O)NC([C@H](C1)N2C[C@@H]1Oc1c(ccc(OC)c3)c3nc(C(OC)=O)c1)=O)C2=O)=O)(=O)=O CGSLOQAKUSYPLZ-SKQVRNOWSA-N 0.000 description 1
- UDFPVDTZJWYHGK-DTXFWFLVSA-N CC(C)(C)[C@@H](CNC)NC(N[C@@H](CCCCC/C=C\C(C1)[C@]1(C(OC)=O)NC([C@H]1N2CCC1)=O)C2=O)=O Chemical compound CC(C)(C)[C@@H](CNC)NC(N[C@@H](CCCCC/C=C\C(C1)[C@]1(C(OC)=O)NC([C@H]1N2CCC1)=O)C2=O)=O UDFPVDTZJWYHGK-DTXFWFLVSA-N 0.000 description 1
- AUNXFHIFDYJHME-UHFFFAOYSA-N CC(C)C(C(C1CC1)=O)NC(NC(CCCCCCCC(C1)C1(C(O)=[O]S1C(NC(C)C)=NC(c2cc(O)c(CCC(OC)=C3)c3n2)=C1)NC(C1N2CCC1)=O)C2=O)=O Chemical compound CC(C)C(C(C1CC1)=O)NC(NC(CCCCCCCC(C1)C1(C(O)=[O]S1C(NC(C)C)=NC(c2cc(O)c(CCC(OC)=C3)c3n2)=C1)NC(C1N2CCC1)=O)C2=O)=O AUNXFHIFDYJHME-UHFFFAOYSA-N 0.000 description 1
- BQNWWTOBSMTONL-UHFFFAOYSA-N CC(C)C(CN(CCC1)C1=O)NC(NC(CCCCCC=CC(C1)C1(C(O)=[O]S1C(NC(C)C)=NC(c2nc3cc(OC)ccc3c(O)c2)=C1)NC(C1(C)N2CCC1)=O)C2=O)=O Chemical compound CC(C)C(CN(CCC1)C1=O)NC(NC(CCCCCC=CC(C1)C1(C(O)=[O]S1C(NC(C)C)=NC(c2nc3cc(OC)ccc3c(O)c2)=C1)NC(C1(C)N2CCC1)=O)C2=O)=O BQNWWTOBSMTONL-UHFFFAOYSA-N 0.000 description 1
- BSWHBKREXKZDEX-UHFFFAOYSA-N CC(C)NC(SC1)=NC1c1nc2cc(OC)ccc2c(O)c1 Chemical compound CC(C)NC(SC1)=NC1c1nc2cc(OC)ccc2c(O)c1 BSWHBKREXKZDEX-UHFFFAOYSA-N 0.000 description 1
- QVRASWUDYCNRKB-UHFFFAOYSA-N CC(C)NC1=NC(c2nc(cc(cc3)O)c3c(O)c2)=CS1[O]=C(C(C1)(C1CCCCCCCC(C(N1C2CCC1)=O)NC(NC(C1CCCCC1)C(C1CC1)=O)=O)NC2=O)O Chemical compound CC(C)NC1=NC(c2nc(cc(cc3)O)c3c(O)c2)=CS1[O]=C(C(C1)(C1CCCCCCCC(C(N1C2CCC1)=O)NC(NC(C1CCCCC1)C(C1CC1)=O)=O)NC2=O)O QVRASWUDYCNRKB-UHFFFAOYSA-N 0.000 description 1
- RZIVIJJEPVTAQJ-UHFFFAOYSA-N CC(C)NC1=NC(c2nc(cc(cc3)OC)c3c(O)c2)=CS1[O]=C(C(C1)(C1C=CCCCCCC(C(N1C2CCC1)=O)NC(NC(C1CCCCC1)C(C1CC1)=O)=O)NC2=O)O Chemical compound CC(C)NC1=NC(c2nc(cc(cc3)OC)c3c(O)c2)=CS1[O]=C(C(C1)(C1C=CCCCCCC(C(N1C2CCC1)=O)NC(NC(C1CCCCC1)C(C1CC1)=O)=O)NC2=O)O RZIVIJJEPVTAQJ-UHFFFAOYSA-N 0.000 description 1
- XPMSYNYISPWSOM-UHFFFAOYSA-N CC(C)NC1=NC(c2nc(cc(cc3)OC)c3c(O)c2)=CS1[O]=C(C(CC1)(C1CCCCCCC(C(N1C2CCC1)=O)NC(NC(CN(Cc1ccccc11)S1(=O)=O)C(C)(C)C)=O)NC2=O)O Chemical compound CC(C)NC1=NC(c2nc(cc(cc3)OC)c3c(O)c2)=CS1[O]=C(C(CC1)(C1CCCCCCC(C(N1C2CCC1)=O)NC(NC(CN(Cc1ccccc11)S1(=O)=O)C(C)(C)C)=O)NC2=O)O XPMSYNYISPWSOM-UHFFFAOYSA-N 0.000 description 1
- NAIBIRXPDWBNRC-UHFFFAOYSA-N CC(C)NC1=NC(c2nc3cc(O)ccc3c(O)c2)=CS1[O]=C(C(C1)(C1C=CCCCCCC(C(N1C2CCC1)=O)NC(NC(CN(C)S(C)(=O)=O)C(C)(C)C)=O)NC2=O)O Chemical compound CC(C)NC1=NC(c2nc3cc(O)ccc3c(O)c2)=CS1[O]=C(C(C1)(C1C=CCCCCCC(C(N1C2CCC1)=O)NC(NC(CN(C)S(C)(=O)=O)C(C)(C)C)=O)NC2=O)O NAIBIRXPDWBNRC-UHFFFAOYSA-N 0.000 description 1
- XHTNAVNCXVPRGZ-UHFFFAOYSA-N CC(C)NC1=NC(c2nc3cc(OC)ccc3c(O)c2)=CS1[O]=C(C(C1)(C1C=CCCCCC=C)NC(C(C)(CCC1)N1C(CNC(NC(C1CCCCC1)C(c(cc1)ccc1N(C)C)=O)=O)=O)=O)O Chemical compound CC(C)NC1=NC(c2nc3cc(OC)ccc3c(O)c2)=CS1[O]=C(C(C1)(C1C=CCCCCC=C)NC(C(C)(CCC1)N1C(CNC(NC(C1CCCCC1)C(c(cc1)ccc1N(C)C)=O)=O)=O)=O)O XHTNAVNCXVPRGZ-UHFFFAOYSA-N 0.000 description 1
- BSNPCBDPDZUKEA-UHFFFAOYSA-N CC(C)NC1=NC(c2nc3cc(OC)ccc3c(O)c2)=CS1[O]=C(C(C1)(C1C=CCCCCCC(C(N1C2(C)CCC1)=O)NC(NC(C1CCCCC1)C(c(cc1)ccc1F)=O)=O)NC2=O)O Chemical compound CC(C)NC1=NC(c2nc3cc(OC)ccc3c(O)c2)=CS1[O]=C(C(C1)(C1C=CCCCCCC(C(N1C2(C)CCC1)=O)NC(NC(C1CCCCC1)C(c(cc1)ccc1F)=O)=O)NC2=O)O BSNPCBDPDZUKEA-UHFFFAOYSA-N 0.000 description 1
- XJOFWYVQNBUENY-UHFFFAOYSA-N CC(C)NC1=NC(c2nc3cc(OC)ccc3c(O)c2)=CS1[O]=C(C(C1)(C1C=CCCCCCC1NC(NC(CN(CCCN2C)S2(=O)=O)C2CCC2)=O)NCC(CCC2)(C=O)N2C1=O)O Chemical compound CC(C)NC1=NC(c2nc3cc(OC)ccc3c(O)c2)=CS1[O]=C(C(C1)(C1C=CCCCCCC1NC(NC(CN(CCCN2C)S2(=O)=O)C2CCC2)=O)NCC(CCC2)(C=O)N2C1=O)O XJOFWYVQNBUENY-UHFFFAOYSA-N 0.000 description 1
- HGANRDWWGVSCMD-UHFFFAOYSA-N CC(C)NC1=NC(c2nc3cc(OC)ccc3c(O)c2)=CS1[O]=C(C(C1)(C1CCCCCCCC(C(N1C2CCC1)=O)NC(NC(CN(C)S(c1ccc[s]1)(=O)=O)C(C)(C)C)=O)NC2=O)O Chemical compound CC(C)NC1=NC(c2nc3cc(OC)ccc3c(O)c2)=CS1[O]=C(C(C1)(C1CCCCCCCC(C(N1C2CCC1)=O)NC(NC(CN(C)S(c1ccc[s]1)(=O)=O)C(C)(C)C)=O)NC2=O)O HGANRDWWGVSCMD-UHFFFAOYSA-N 0.000 description 1
- UFBBPYDFDJEZLP-UHFFFAOYSA-N CC(C)NC1=NC(c2nc3cc(OC)ccc3c(O)c2)=CS1[O]=C(C(C1)(C1CCCCCCCC(C(N1C2CCC1)=O)NC(NC(CN(CCC1)S1(=O)=O)C(C)(C)C)=O)NC2=O)O Chemical compound CC(C)NC1=NC(c2nc3cc(OC)ccc3c(O)c2)=CS1[O]=C(C(C1)(C1CCCCCCCC(C(N1C2CCC1)=O)NC(NC(CN(CCC1)S1(=O)=O)C(C)(C)C)=O)NC2=O)O UFBBPYDFDJEZLP-UHFFFAOYSA-N 0.000 description 1
- GZELHEVBLMVMIX-UHFFFAOYSA-N CC(C)NCCN(CC(C(C)(C)C)OC(NC(CCCCCC=CC(C1)C1(C(O)=O)NC(C1N2CCC1)=O)C2=O)=O)S(=O)=O Chemical compound CC(C)NCCN(CC(C(C)(C)C)OC(NC(CCCCCC=CC(C1)C1(C(O)=O)NC(C1N2CCC1)=O)C2=O)=O)S(=O)=O GZELHEVBLMVMIX-UHFFFAOYSA-N 0.000 description 1
- JKWWCVTVUYXQFM-WXNHPUBWSA-N CC(C)Nc1nc(-c2nc(C=C(CC3)OC)c3c(OC(CC3(C)C(N[C@](C4)(C4CCCCCCC[C@@H]4NC(NC(CN(C)S(C(C)C)(=O)=O)C(C)(C)C)=O)C(O)=O)=O)CN3C4=O)c2)c[s]1 Chemical compound CC(C)Nc1nc(-c2nc(C=C(CC3)OC)c3c(OC(CC3(C)C(N[C@](C4)(C4CCCCCCC[C@@H]4NC(NC(CN(C)S(C(C)C)(=O)=O)C(C)(C)C)=O)C(O)=O)=O)CN3C4=O)c2)c[s]1 JKWWCVTVUYXQFM-WXNHPUBWSA-N 0.000 description 1
- JODNLWGGRDMBAV-DTFRMIBWSA-N CC(C)Nc1nc(-c2nc(cc(cc3)OC)c3c(OC(CC3(C)C(N[C@](C4)(C4/C=C\CCCCC[C@@H]4NC(NC(CN(C)S(c5ccccc5)(=O)=O)C5CCC5)=O)C(O)=O)=O)CN3C4=O)c2)c[s]1 Chemical compound CC(C)Nc1nc(-c2nc(cc(cc3)OC)c3c(OC(CC3(C)C(N[C@](C4)(C4/C=C\CCCCC[C@@H]4NC(NC(CN(C)S(c5ccccc5)(=O)=O)C5CCC5)=O)C(O)=O)=O)CN3C4=O)c2)c[s]1 JODNLWGGRDMBAV-DTFRMIBWSA-N 0.000 description 1
- ICCXDTKGUDPEDE-PQQHPOOLSA-N CC(C)Nc1nc(-c2nc(cc(cc3)OC)c3c(OC(CC3(C)C=O)CN3C([C@H](CCCCCCCC(C3)[C@]3(C(O)=O)N)NC(NC(CN(C)S(c3ccc[s]3)(=O)=O)C3CCCCC3)=O)=O)c2)c[s]1 Chemical compound CC(C)Nc1nc(-c2nc(cc(cc3)OC)c3c(OC(CC3(C)C=O)CN3C([C@H](CCCCCCCC(C3)[C@]3(C(O)=O)N)NC(NC(CN(C)S(c3ccc[s]3)(=O)=O)C3CCCCC3)=O)=O)c2)c[s]1 ICCXDTKGUDPEDE-PQQHPOOLSA-N 0.000 description 1
- YCZTXINGXLBAIS-UHFFFAOYSA-N CC(C)Nc1nc(-c2nc3cc(O)ccc3c(O)c2)c[s]1 Chemical compound CC(C)Nc1nc(-c2nc3cc(O)ccc3c(O)c2)c[s]1 YCZTXINGXLBAIS-UHFFFAOYSA-N 0.000 description 1
- QDULKWNBWGMHNS-UHFFFAOYSA-N CC(C)Nc1nc(-c2nc3cc(OC)ccc3c(C)c2)c[s]1 Chemical compound CC(C)Nc1nc(-c2nc3cc(OC)ccc3c(C)c2)c[s]1 QDULKWNBWGMHNS-UHFFFAOYSA-N 0.000 description 1
- BHXQNMQMHZFDBX-UHFFFAOYSA-N CC(C)Nc1scc(-c2nc3cc(OC)ccc3c([O]=C)c2)[nH]1 Chemical compound CC(C)Nc1scc(-c2nc3cc(OC)ccc3c([O]=C)c2)[nH]1 BHXQNMQMHZFDBX-UHFFFAOYSA-N 0.000 description 1
- OMOSUHXOXZLIDO-LYQVRKTCSA-N CC([C@@H](C(C1CC1)=O)NC(N[C@@H](CCCCC/C=C\C(C1)[C@]1(C(O)=O)NC([C@H]1N2CCC1)=O)C2=O)=O)=C Chemical compound CC([C@@H](C(C1CC1)=O)NC(N[C@@H](CCCCC/C=C\C(C1)[C@]1(C(O)=O)NC([C@H]1N2CCC1)=O)C2=O)=O)=C OMOSUHXOXZLIDO-LYQVRKTCSA-N 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N CCN(C(CC1)=O)C1=O Chemical compound CCN(C(CC1)=O)C1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- FYOBXCNUOFGTIJ-ZQESCHAHSA-N CC[C@@H](C(O)=O)NC([C@H](C[C@H](C1)Oc2cc(-c3c[s]c(NC(C)C)n3)nc(C3)c2[C@@H]3OC)N1C([C@H](CCCC(C)C)NC(NC1(CS(C(C)(C)C)(=O)=O)CCCCC1)=O)=O)=O Chemical compound CC[C@@H](C(O)=O)NC([C@H](C[C@H](C1)Oc2cc(-c3c[s]c(NC(C)C)n3)nc(C3)c2[C@@H]3OC)N1C([C@H](CCCC(C)C)NC(NC1(CS(C(C)(C)C)(=O)=O)CCCCC1)=O)=O)=O FYOBXCNUOFGTIJ-ZQESCHAHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
Definitions
- HCV hepatitis C virus
- M is O, N(H), or CH 2 ; n is 0-4; H
- R moieties can be the same or different, each R 8 being independently selected from the group consisting of hydrogen, alkyl, heteroalkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, hydroxyl, amino, arylamino, alkylamino, dialkylamino, halo, alkylthio, arylthio and alkyloxy.
- R 4 and R 5 are the same or different, each being independently selected from the group consisting of:
- M is NH.
- n is 0 or 1.
- R 1 is OH, NH 2 or N(H)(alkyl).
- P- ⁇ is cyclopropylalkyl, cyclobutylalkyl, n- propyl, n-butyl, 1 ,1 ,-difluoroethyl, 1 ,1-difluoropropyl or 1 ,1 ,1 -trifluoropropyl.
- alkyl means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain. More preferred alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain.
- “Lower alkyl” means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched.
- substituted alkyl means that the alkyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, -NH(alkyl), -NH(cycloalkyl), -N(alkyl) 2 , -N(alkyl) 2 , carboxy and -C(0)0- alkyl.
- “Lower alkynyl” means about 2 to about 6 carbon atoms in the chain which may be straight or branched.
- suitable alkynyl groups include ethynyl, propynyl, 2-butynyl and 3- methyl butynyl.
- substituted alkynyl means that the alkynyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of alkyl, aryl and cycloalkyl.
- “Aryl” means an aromatic monocyclic or multicyclic ring system comprising about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms.
- the aryl group can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined herein.
- suitable aryl groups include phenyl and naphthyl.
- Heteroaryl means an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination.
- Preferred heteroaryls contain about 5 to about 6 ring atoms.
- heteroaryl can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein.
- ring system substituents which may be the same or different, and are as defined herein.
- the prefix aza, oxa or thia before the heteroaryl root name means that at least a nitrogen, oxygen or sulfur atom respectively, is present as a ring atom.
- a nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide.
- Non- limiting examples of suitable heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1 ,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, oxindolyl, imidazo[1 ,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thienopyri
- Preferred alkylaryls comprise a lower alkyl group.
- Non- limiting example of a suitable alkylaryl group is tolyl.
- the bond to the parent moiety is through the aryl.
- Cycloalkyl means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms.
- Preferred cycloalkyl rings contain about 5 to about 7 ring atoms.
- the cycloalkyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above.
- Non-limiting examples of suitable monocyclic cycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
- Non-limiting examples of suitable multicyclic cycloalkyls include 1-decalinyl, norbornyl, adamantyl and the like, as well as partially saturated species such as, for example, indanyl, tetrahydronaphthyl and the like.
- "Halogen” means fluorine, chlorine, bromine, or iodine. Preferred are fluorine, chlorine and bromine.
- Ring system substituent means a substituent attached to an aromatic or non-aromatic ring system which, for example, replaces an available hydrogen on the ring system.
- Ring system substituents may be the same or different, each being independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, alkylaryl, heteroaralkyl, heteroarylalkenyl, heteroarylalkynyl, alkylheteroaryl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylthio, arylthio, heteroarylthio, aralkylthio
- Ring system substituent may also mean a single moiety which simultaneously replaces two available hydrogens on two adjacent carbon atoms (one H on each carbon) on a ring system.
- Examples of such moiety are methylene dioxy, ethylenedioxy, -C(CH 3 ) 2 - and the like which form moieties such as, for example:
- Heterocyclyl means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system.
- Preferred heterocyclyls contain about 5 to about 6 ring atoms.
- the prefix aza, oxa or thia before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom.
- Non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1 ,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, lactam, lactone, and the like. It should be noted that in hetero-atom containing ring systems of this invention, there are no hydroxyl groups on carbon atoms adjacent to a N, O or S, as well as there are no N or S groups on carbon adjacent to another heteroatom. Thus, for example, in the ring:
- Alkynylalkyl means an alkynyl-alkyl- group in which the alkynyl and alkyl are as previously described. Preferred alkynylalkyls contain a lower alkynyl and a lower alkyl group. The bond to the parent moiety is through the alkyl. Non-limiting examples of suitable alkynylalkyl groups include propargylmethyl.
- Heteroaralkyl means a heteroaryl-alkyl- group in which the heteroaryl and alkyl are as previously described. Preferred heteroaralkyls contain a lower alkyl group.
- Non-limiting examples of suitable aralkyl groups include pyridylmethyl, and quinolin-3-ylmethyl.
- the bond to the parent moiety is through the alkyl.
- "Hydroxyalkyl” means a HO-alkyl- group in which alkyl is as previously defined.
- Preferred hydroxyalkyls contain lower alkyl.
- suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.
- “Acyl” means an H-C(O)-, alkyl-C(O)- or cycloalkyl-C(O)-, group in which the various groups are as previously described.
- the bond to the parent moiety is through the carbonyl.
- Preferred acyls contain a lower alkyl.
- Non- limiting examples of suitable acyl groups include formyl, acetyl and propanoyl.
- “Aroyl” means an aryl-C(O)- group in which the aryl group is as previously described. The bond to the parent moiety is through the carbonyl.
- suitable groups include benzoyl and 1- naphthoyl.
- Alkoxy means an alkyl-O- group in which the alkyl group is as previously described.
- suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy. The bond to the parent moiety is through the ether oxygen.
- Aryloxy means an aryl-O- group in which the aryl group is as previously described.
- suitable aryloxy groups include phenoxy and naphthoxy.
- the bond to the parent moiety is through the ether oxygen.
- Aralkyloxy means an aralkyl-O- group in which the aralkyl group is as previously described.
- suitable aralkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy.
- the bond to the parent moiety is through the ether oxygen.
- Alkylthio means an alkyl-S- group in which the alkyl group is as previously described.
- Non-limiting examples of suitable alkylthio groups include methylthio and ethylthio.
- the bond to the parent moiety is through the sulfur.
- Arylthio means an aryl-S- group in which the aryl group is as previously described.
- suitable arylthio groups include phenylthio and naphthylthio.
- the bond to the parent moiety is through the sulfur.
- Aralkylthio means an aralkyl-S- group in which the aralkyl group is as previously described.
- Non-limiting example of a suitable aralkylthio group is benzylthio.
- the bond to the parent moiety is through the sulfur.
- Alkoxycarbonyl means an alkyl-O-CO- group. Non-limiting examples of suitable alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl. The bond to the parent moiety is through the carbonyl.
- Aryloxycarbonyl means an aryl-O-C(O)- group. Non-limiting examples of suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl. The bond to the parent moiety is through the carbonyl.
- Aralkoxycarbonyl means an aralkyl-O-C(O)- group. Non-limiting example of a suitable aralkoxycarbonyl group is benzyloxycarbonyl.
- alkylsulfonyl means an alkyl-S(0 2 )- group. Preferred groups are those in which the alkyl group is lower alkyl.
- the bond to the parent moiety is through the sulfonyl.
- Arylsulfonyl means an aryl-S(0 2 )- group. The bond to the parent moiety is through the sulfonyl.
- substituted means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound.
- purified or "in purified form” for a compound refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan, in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan. It should also be noted that any heteroatom with unsatisfied valences in the text, schemes, examples and Tables herein is assumed to have the hydrogen atom(s) to satisfy the valences. When a functional group in a compound is termed "protected”, this means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction.
- Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene eif al, Protective Groups in organic Synthesis (1991), Wiley, New York.
- any variable e.g., aryl, heterocycle, R 2 , etc.
- its definition on each occurrence is independent of its definition at every other occurrence.
- composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
- Prodrugs and solvates of the compounds of the invention are also contemplated herein.
- prodrug denotes a compound that is a drug precursor which, upon administration to a subject, undergoes chemical conversion by metabolic or chemical processes to yield a compound of Formulas 1 , 2 or 3 or a salt and/or solvate thereof.
- a discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press, both of which are incorporated herein by reference thereto.
- Solvate means a physical association of a compound of this invention with one or more solvent molecules.
- solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid.
- Solvate encompasses both solution-phase and isolatable solvates.
- suitable solvates include ethanolates, methanolates, and the like.
- Hydrophile amount is meant to describe an amount of compound or a composition of the present invention effective in inhibiting the CDK(s) and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect.
- the compounds of Formulas 1 , 2 or 3 can form salts which are also within the scope of this invention.
- Reference to a compound of Formulas 1 , 2 or 3 herein is understood to include reference to salts thereof, unless otherwise indicated.
- the term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases.
- a compound of Formulas 1 , 2 or 3 contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term “salt(s)" as used herein.
- Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful.
- Salts of the compounds of the Formulas 1 , 2 or 3 may be formed, for example, by reacting a compound of Formulas 1 , 2 or 3 with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
- Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like.
- Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like.
- Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g.
- esters of the present compounds include the following groups: (1 ) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted with, for example, halogen, C-i- alkyl, or C ⁇ -4 alkoxy or amino); (2) sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl); (3) amino acid esters (for example, L-valyl or L-isoleucyl);
- the phosphate esters may be further esterified by, for example, a C 1-20 alcohol or reactive derivative thereof, or by a 2,3-di (C 6-24 )acyl glycerol.
- Compounds of Formulas 1 , 2 or 3, and salts, solvates and prodrugs thereof, may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention.
- All stereoisomers for example, geometric isomers, optical isomers and the like
- of the present compounds including those of the salts, solvates and prodrugs of the compounds as well as the salts and solvates of the prodrugs
- those which may exist due to asymmetric carbons on various substituents including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl).
- Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers.
- the chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations.
- the use of the terms "salt”, “solvate” "prodrug” and the like, is intended to equally apply to the salt, solvate and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.
- the compounds according to the invention can have pharmacological properties; in particular, the compounds of Formulas 1 , 2 or 3 can be inhibitors of HCV protease, each compound by itself or one or more compounds of Formulas 1 , 2 or 3 can be combined with one or more compounds selected from within Formula 1 , or from within Formula 2 or from within Formula 3.
- the compound(s) can be useful for treating diseases such as, for example, HCV, HIV, (AIDS, Acquired Immune Deficiency Syndrome), and related disorders, as well as for modulating the activity of hepatitis C virus (HCV) protease, preventing HCV, or ameliorating one or more symptoms of hepatitis C.
- HCV hepatitis C virus
- the compounds of Formulas 1 , 2 or 3 may be used for the manufacture of a medicament to treat disorders associated with the HCV protease, for example, the method comprising bringing into intimate contact a compound of Formulas 1 , 2 or 3 a pharmaceutically acceptable carrier.
- this invention provides pharmaceutical compositions comprising the inventive compound or compounds as an active ingredient.
- the pharmaceutical compositions generally additionally comprise at least one pharmaceutically acceptable carrier diluent, excipient or carrier (collectively referred to herein as carrier materials). Because of their HCV inhibitory activity, such pharmaceutical compositions possess utility in treating hepatitis C and related disorders.
- the present invention discloses methods for preparing pharmaceutical compositions comprising the inventive compounds as an active ingredient.
- the active ingredients will typically be administered in admixture with suitable carrier materials suitably selected with respect to the intended form of administration, i.e. oral tablets, capsules (either solid-filled, semi-solid filled or liquid filled), powders for constitution, oral gels, elixirs, dispersible granules, syrups, suspensions, and the like, and consistent with conventional pharmaceutical practices.
- suitable carrier materials suitably selected with respect to the intended form of administration, i.e. oral tablets, capsules (either solid-filled, semi-solid filled or liquid filled), powders for constitution, oral gels, elixirs, dispersible granules, syrups, suspensions, and the like, and consistent with conventional pharmaceutical practices.
- the active drug component may be combined with any oral non-toxic pharmaceutically acceptable inert carrier, such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid forms) and the like.
- suitable binders, lubricants, disintegrating agents and coloring agents may also be incorporated in the mixture.
- Powders and tablets may be comprised of from about 5 to about 95 percent inventive composition.
- compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimize the therapeutic effects, i.e. HCV inhibitory activity and the like.
- Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.
- Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injections or addition of sweeteners and pacifiers for oral solutions, suspensions and emulsions.
- Liquid form preparations may also include solutions for intranasal administration.
- Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier such as inert compressed gas, e.g. nitrogen.
- a pharmaceutically acceptable carrier such as inert compressed gas, e.g. nitrogen.
- a low melting wax such as a mixture of fatty acid glycerides such as cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein by stirring or similar mixing. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.
- solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration.
- Such liquid forms include solutions, suspensions and emulsions.
- the compounds of the invention may also be deliverable transdermally.
- the transdermal compositions may take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
- the compounds of the invention may also be administered orally, intravenously, intranasally or subcutaneously.
- the compounds of the invention may also comprise preparations which are in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose.
- the quantity of the inventive active composition in a unit dose of preparation may be generally varied or adjusted from about 1.0 milligram to about 1 ,000 milligrams, preferably from about 1.0 to about 950 milligrams, more preferably from about 1.0 to about 500 milligrams, and typically from about 1 to about 250 milligrams, according to the particular application.
- the actual dosage employed may be varied depending upon the patient's age, sex, weight and severity of the condition being treated. Such techniques are well known to those skilled in the art.
- the human oral dosage form containing the active ingredients can be administered 1 or 2 times per day. The amount and frequency of the administration will be regulated according to the judgment of the attending clinician.
- a generally recommended daily dosage regimen for oral administration may range from about 1.0 milligram to about 1 ,000 milligrams per day, in single or divided doses.
- Capsule - refers to a special container or enclosure made of methyl cellulose, polyvinyl alcohols, or denatured gelatins or starch for holding or containing compositions comprising the active ingredients.
- Hard shell capsules are typically made of blends of relatively high gel strength bone and pork skin gelatins. The capsule itself may contain small amounts of dyes, opaquing agents, plasticizers and preservatives.
- Tablet- refers to a compressed or molded solid dosage form containing the active ingredients with suitable diluents.
- the tablet can be prepared by compression of mixtures or granulations obtained by wet granulation, dry granulation or by compaction.
- Oral gel- refers to the active ingredients dispersed or solubilized in a hydrophillic semi-solid matrix.
- Powder for constitution refers to powder blends containing the active ingredients and suitable diluents which can be suspended in water or juices.
- Diluent - refers to substances that usually make up the major portion of the composition or dosage form. Suitable diluents include sugars such as lactose, sucrose, mannitol and sorbitol; starches derived from wheat, corn, rice and potato; and celluloses such as microcrystalline cellulose.
- the amount of diluent in the composition can range from about 10 to about 90% by weight of the total composition, preferably from about 25 to about 75%, more preferably from about 30 to about 60% by weight, even more preferably from about 12 to about 60%.
- Disintegrant - refers to materials added to the composition to help it break apart (disintegrate) and release the medicaments.
- Suitable disintegrants include starches; "cold water soluble” modified starches such as sodium carboxymethyl starch; natural and synthetic gums such as locust bean, karaya, guar, tragacanth and agar; cellulose derivatives such as methylcellulose and sodium carboxymethylcellulose; microcrystalline celluloses and cross-linked microcrystalline celluloses such as sodium croscarmellose; alginates such as alginic acid and sodium alginate; clays such as bentonites; and effervescent mixtures.
- the amount of disintegrant in the composition can range from about 2 to about 15% by weight of the composition, more preferably from about 4 to about 10% by weight.
- Binder - refers to substances that bind or "glue” powders together and make them cohesive by forming granules, thus serving as the "adhesive" in the formulation. Binders add cohesive strength already available in the diluent or bulking agent. Suitable binders include sugars such as sucrose; starches derived from wheat, corn rice and potato; natural gums such as acacia, gelatin and tragacanth; derivatives of seaweed such as alginic acid, sodium alginate and ammonium calcium alginate; cellulosic materials such as methylcellulose and sodium carboxymethylcellulose and hydroxypropylmethylcellulose; polyvinylpyrrolidone; and inorganics such as magnesium aluminum silicate.
- sugars such as sucrose
- starches derived from wheat, corn rice and potato natural gums such as acacia, gelatin and tragacanth
- derivatives of seaweed such as alginic acid, sodium alginate and ammonium calcium alginate
- the amount of binder in the composition can range from about 2 to about 20% by weight of the composition, more preferably from about 3 to about 10% by weight, even more preferably from about 3 to about 6% by weight.
- Lubricant - refers to a substance added to the dosage form to enable the tablet, granules, etc. after it has been compressed, to release from the mold or die by reducing friction or wear.
- Suitable lubricants include metallic stearates such as magnesium stearate, calcium stearate or potassium stearate; stearic acid; high melting point waxes; and water soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and d'l-leucine.
- Lubricants are usually added at the very last step before compression, since they must be present on the surfaces of the granules and in between them and the parts of the tablet press.
- the amount of lubricant in the composition can range from about 0.2 to about 5% by weight of the composition, preferably from about 0.5 to about 2%, more preferably from about 0.3 to about 1.5% by weight.
- Glident - material that prevents caking and improve the flow characteristics of granulations, so that flow is smooth and uniform. Suitable glidents include silicon dioxide and talc.
- the amount of glident in the composition can range from about 0.1 % to about 5% by weight of the total composition, preferably from about 0.5 to about 2% by weight.
- Coloring agents - excipients that provide coloration to the composition or the dosage form.
- excipients can include food grade dyes and food grade dyes adsorbed onto a suitable adsorbent such as clay or aluminum oxide.
- the amount of the coloring agent can vary from about 0.1 to about 5% by weight of the composition, preferably from about 0.1 to about 1 %.
- Bioavailability - refers to the rate and extent to which the active drug ingredient or therapeutic moiety is absorbed into the systemic circulation from an administered dosage form as compared to a standard or control.
- Conventional methods for preparing tablets are known. Such methods include dry methods such as direct compression and compression of granulation produced by compaction, or wet methods or other special procedures.
- inventive compounds or pharmaceutical compositions disclosed above for treatment of diseases such as, for example, hepatitis C and the like.
- the method comprises administering a therapeutically effective amount of the inventive compound or pharmaceutical composition to a patient having such a disease or diseases and in need of such a treatment.
- the compounds of the invention may be used for the treatment of HCV in humans in monotherapy mode or in a combination therapy (e.g., dual combination, triple combination etc.) mode such as, for example, in combination with antiviral and/or immunomodulatory agents.
- antiviral and/or immunomodulatory agents examples include Ribavirin (from Schering-Plough Corporation, Madison, New Jersey) and LevovirinTM (from ICN Pharmaceuticals, Costa Mesa, California), VP 50406TM (from Viropharma, Incorporated, Exton, Pennsylvania), ISIS 14803TM (from ISIS Pharmaceuticals, Carlsbad, California), HeptazymeTM (from Ribozyme Pharmaceuticals, Boulder, Colorado), VX 497TM (from Vertex Pharmaceuticals, Cambridge, Massachusetts), ThymosinTM (from SciClone Pharmaceuticals, San Mateo, California), MaxamineTM (Maxim Pharmaceuticals, San Diego, California), mycophenolate mofetil (from Hoffman-LaRoche, Nutley, New Jersey), interferon (such as, for example, interferon-alpha, PEG-interferon alpha conjugates) and the like.
- Ribavirin from Schering-Plough Corporation, Madison, New Jersey
- LevovirinTM from ICN Pharmaceuticals, Costa Mesa, California
- PEG- interferon alpha conjugates are interferon alpha molecules covalently attached to a PEG molecule.
- Illustrative PEG-interferon alpha conjugates include interferon alpha-2a (RoferonTM, from Hoffman La-Roche, Nutley, New Jersey) in the form of pegylated interferon alpha-2a (e.g., as sold under the trade name PegasysTM), interferon alpha-2b (IntronTM, from Schering-Plough Corporation) in the form of pegylated interferon alpha-2b (e.g., as sold under the trade name PEG-lntronTM), interferon alpha-2c (Berofor AlphaTM, from Boehringer Ingelheim, Ingelheim, Germany) or consensus interferon as defined by determination of a consensus sequence.
- interferon alpha-2a RosferonTM, from Hoffman La-Roche, Nutley, New Jersey
- PegasysTM interferon alpha-2b
- the therapeutic agents in the combination, or a pharmaceutical composition or compositions comprising the therapeutic agents may be administered in any order such as, for example, sequentially, concurrently, together, simultaneously and the like.
- the amounts of the various actives in such combination therapy may be different amounts (different dosage amounts) or same amounts (same dosage amounts).
- a compound of Formula I and an additional therapeutic agent may be present in fixed amounts (dosage amounts) in a single dosage unit (e.g., a capsule, a tablet and the like).
- VYTORIN ® available from Merck Schering-Plough Pharmaceuticals, Kenilworth, New Jersey.
- the invention includes tautomers, rotamers, enantiomers and other stereoisomers of the inventive compounds also.
- some of the inventive compounds may exist in suitable isomeric forms. Such variations are contemplated to be within the scope of the invention.
- Another embodiment of the invention discloses a method of making the compounds disclosed herein. The compounds may be prepared by several techniques known in the art. Illustrative procedures are outlined in the following reaction schemes. The illustrations should not be construed to limit the scope of the invention which is defined in the appended claims.
- DCM means diclhloromethane
- DCC 1 ,3-Dicyclohexylcarbodiimide
- DMF means ⁇ /, ⁇ /-dimethylformamide
- DMSO means dimethyl sulfoxide
- EDCI 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
- HATU means 0-(7-azabenzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium
- HOOBt 3-Hydroxy-1 ,2,3-benzotriazin-4(3H)-one; HOBt: N-Hydroxybenzotriazole; iBoc: isobutoxycarbonyl; iPr: isopropyl;
- KHMDS means Potassium hexamethyl disilylamide
- LiHMDS means hexamethyldisilazide
- MS means mass spectrum
- nBuLi means n-butyl lithium
- NMM means N-methyl morpholine
- NMR nuclear magnetic resonance
- Phg Phenylglycine
- Ph Phenyl
- Pd/C means palladium on charcoal catalyst
- TBuNCO means t-butyl isocyanate
- TEMPO 2,2,6,6-Tetramethyl-1 -piperidinyloxy
- THF means tetrahydrofuran
- THP means tetrahydrofuran
- TMSI means trimethyl silyl iodide
- T 3 N means triethylamine
- Ts p-toluenesulfonyl.
- a solution methanesulfonamide Id (1.0 g, 2.9 mmol) in methanol (30 mL) is treated with palladium (200 mg, 10% wt/C) and hydrogenated at 60 psi for 3 h.
- the reaction mixture is filtered through a plug of celite and the filtrate is concentrated in vacuo. The residue is directly used in further reaction without further purification.
- a solution of deprotected amine in CH 2 CI 2 (10 mL) aq. saturated NaHC0 3 (10 mL) at 0°C is treated with phosgene (5 mL, 15% soln. in toluene) and stirred at 0 °C for 2 h.
- a solution of sodium salt l ⁇ jn dry THF is cooled to 0 °C and treated with Et 3 N and isobutylchloroformate.
- the reaction is stirred at 0 °C for 1.25 h and treated with diazomethane and stirred at 0 °C for 1 h and rt for.
- the reaction mixture is quenched with acetic acid and taken up with EtOAc.
- the organic layer is washed with satd. aq. NaHC0 3, brine, and dried (MgS0 4 ). It is filtered and concentrated in vacuo to yield diazo ketone which is directly used in next reaction without purification.
- a solution of diazo compound in THF is cooled to 0 °C and treated with aq.
- Boc protected compound 2a (WO 00/09558 (Boehringer Ingelheim, Canada) in HCl (4 M soln in dioxane) and CH2CI2 is stirred at rt. and concentrated in vacuo. The disappearance of starting material is followed by TLC (acetone/hexanes 1 :1). The gelatinous reaction mixture is concentrated in vacuo and dried to yield 2b that is used in next reaction without further purification.
- Aqueous work-up provided a residue which was purified by silica gel column chromatography using EtOAc; hexanes (1 :10) as eluent to give the benzyl ether which was used in the next step (14.98g)
- a black suspension of 10% Pd/C (0.5g) and the aforementioned crude ether (4.1g) in methanol (80 ml) was exposed to an atmosphere of hydrogen (balloon) at room temp, overnight.
- the reaction was filtered through a pad of celite and the solid was washed thoroughly with methanol.
- the combined filtrate was concentrated under reduced pressure and the crude product was purified by silica gel column chromatography using EtOAc; hexanes (1 :5) to give the primary alcohol 3b.
- reaction mixture is concentrated in vacuo and purified by chromatography
- Reagents for peptide synthesis were from Aldrich Chemicals, Novabiochem (San Diego, California), Applied Biosystems (Foster City, California) and Perseptive Biosystems (Framingham, Massachusetts). Peptides are synthesized manually or on an automated ABI model 431 A synthesizer (from Applied Biosystems).
- UV/VIS Spectrometer model LAMBDA 12 was from Perkin Elmer (Norwalk, Connecticut) and 96-well UV plates were obtained from Corning (Corning, New York).
- the prewarming block can be from USA Scientific (Ocala, Florida) and the 96-well plate vortexer is from Labline Instruments (Melrose Park, Illinois).
- Spectramax Plus microtiter plate reader with monochrometer is obtained from Molecular Devices (Sunnyvale, California).
- Enzyme Preparation Recombinant heterodimeric HCV NS3/NS4A protease (strain 1a) is prepared by using the procedures published previously (D. L. Sali et al, Biochemistry, 37 (1998) 3392-3401 ). Protein concentrations are determined by the Biorad dye method using recombinant HCV protease standards previously quantified by amino acid analysis.
- the N-acetylated and fully protected peptide fragments are cleaved from the resin either by 10% acetic acid (HOAc) and 10% trifluoroethanol (TFE) in dichloromethane (DCM) for 30 min, or by 2% trifluoroacetic acid (TFA) in DCM for 10 min.
- the combined filtrate and DCM wash is evaporated azeotropically (or repeatedly extracted by aqueous Na2C03 solution) to remove the acid used in cleavage.
- the DCM phase is dried over Na2S ⁇ 4 and evaporated.
- the ester substrates are assembled using standard acid-alcohol coupling procedures (K. Holmber et al, Acta Chem. Scand., B33 (1979) 410- 412).
- Peptide fragments are dissolved in anhydrous pyridine (30-60 mg/ml) to which 10 molar equivalents of chromophore and a catalytic amount (0.1 eq.) of para-toluenesulfonic acid (pTSA) were added.
- pTSA para-toluenesulfonic acid
- Dicyclohexylcarbodiimide (DCC, 3 eq.) is added to initiate the coupling reactions.
- Product formation is monitored by HPLC and can be found to be complete following 12-72 hour reaction at room temperature. Pyridine solvent is evaporated under vacuum and further removed by azeotropic evaporation with toluene.
- Assay buffer conditions 25 mM MOPS pH 6.5, 300 mM NaCl, 10% glycerol, 0.05% lauryl maltoside, 5 ⁇ M EDTA and 5 ⁇ M DTT are optimized for the NS3/NS4A heterodimer (D. L. Sali et al, ibid.)).
- 150 ⁇ l mixtures of buffer, substrate and inhibitor are placed in wells (final concentration of DMSO ⁇ 4 % v/v) and allowed to preincubate at 30 °C for approximately 3 minutes.
- the plates are monitored over the length of the assay (60 minutes) for change in absorbance at the appropriate wavelength (340 nm for 3-Np and HMC, 370 nm for PAP, and 400 nm for 4-Np) using a Spectromax Plus microtiter plate reader equipped with a monochrometer (acceptable results can be obtained with plate readers that utilize cutoff filters).
- Proteolytic cleavage of the ester linkage between the Nva and the chromophore is monitored at the appropriate wavelength against a no enzyme blank as a control for non-enzymatic hydrolysis.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002546290A CA2546290A1 (en) | 2003-11-20 | 2004-11-19 | Depeptidized inhibitors of hepatitis c virus ns3 protease |
EP04811791A EP1689770A1 (en) | 2003-11-20 | 2004-11-19 | Depeptidized inhibitors of hepatitis c virus ns3 protease |
MXPA06005683A MXPA06005683A (en) | 2003-11-20 | 2004-11-19 | Depeptidized inhibitors of hepatitis c virus ns3 protease. |
JP2006541606A JP2007532479A (en) | 2003-11-20 | 2004-11-19 | Depeptideization inhibitor of hepatitis C virus NS3 protease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52371503P | 2003-11-20 | 2003-11-20 | |
US60/523,715 | 2003-11-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005051980A1 true WO2005051980A1 (en) | 2005-06-09 |
WO2005051980A8 WO2005051980A8 (en) | 2006-09-08 |
Family
ID=34632818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/039131 WO2005051980A1 (en) | 2003-11-20 | 2004-11-19 | Depeptidized inhibitors of hepatitis c virus ns3 protease |
Country Status (7)
Country | Link |
---|---|
US (2) | US7253160B2 (en) |
EP (1) | EP1689770A1 (en) |
JP (1) | JP2007532479A (en) |
CN (1) | CN1902216A (en) |
CA (1) | CA2546290A1 (en) |
MX (1) | MXPA06005683A (en) |
WO (1) | WO2005051980A1 (en) |
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006130666A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
WO2007019674A1 (en) | 2005-08-12 | 2007-02-22 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7449479B2 (en) | 2002-05-20 | 2008-11-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2009076173A2 (en) | 2007-12-05 | 2009-06-18 | Enanta Pharmaceuticals, Inc. | Fluorinated tripeptide hcv serine protease inhibitors |
WO2009076747A1 (en) | 2007-12-19 | 2009-06-25 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2010080874A1 (en) | 2009-01-07 | 2010-07-15 | Scynexis, Inc. | Cyclosporine derivative for use in the treatment of hcv and hiv infection |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2237666A1 (en) * | 2007-12-21 | 2010-10-13 | Avila Therapeutics, Inc. | Hcv protease inhibitors and uses thereof |
US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
WO2010132163A1 (en) | 2009-05-13 | 2010-11-18 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis c virus inhibitors |
KR20100131971A (en) * | 2007-12-21 | 2010-12-16 | 아빌라 테라퓨틱스, 인크. | Hcv protease inhibitors and uses thereof |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7897622B2 (en) | 2006-08-17 | 2011-03-01 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7906513B2 (en) * | 2007-04-26 | 2011-03-15 | Enanta Pharmaceuticals, Inc. | Hydrazide-containing hepatitis C serine protease inhibitors |
US7935670B2 (en) | 2006-07-11 | 2011-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2364984A1 (en) | 2005-08-26 | 2011-09-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
US8044023B2 (en) | 2008-05-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
US8242140B2 (en) | 2007-08-03 | 2012-08-14 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
US8314141B2 (en) | 1996-10-18 | 2012-11-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US8420596B2 (en) | 2008-09-11 | 2013-04-16 | Abbott Laboratories | Macrocyclic hepatitis C serine protease inhibitors |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8937041B2 (en) | 2010-12-30 | 2015-01-20 | Abbvie, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
US8951964B2 (en) | 2010-12-30 | 2015-02-10 | Abbvie Inc. | Phenanthridine macrocyclic hepatitis C serine protease inhibitors |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9333204B2 (en) | 2014-01-03 | 2016-05-10 | Abbvie Inc. | Solid antiviral dosage forms |
US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP3020723A1 (en) | 2010-09-21 | 2016-05-18 | Enanta Pharmaceuticals, Inc. | Macrocyclic proline derived hcv serine protease inhibitors |
US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9499550B2 (en) | 2012-10-19 | 2016-11-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9580463B2 (en) | 2013-03-07 | 2017-02-28 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201541B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
US20070237818A1 (en) * | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
EP1891089B1 (en) | 2005-06-02 | 2014-11-05 | Merck Sharp & Dohme Corp. | HCV protease inhibitors in combination with food |
EP1919478B1 (en) * | 2005-06-02 | 2016-03-23 | Merck Sharp & Dohme Corp. | Combination of hcv protease inhibitors with a surfactant |
EP2305697A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
US7705138B2 (en) * | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
KR20140098867A (en) | 2005-11-11 | 2014-08-08 | 버텍스 파마슈티칼스 인코포레이티드 | Hepatitis c virus variants |
US9526769B2 (en) * | 2006-06-06 | 2016-12-27 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
UY30437A1 (en) * | 2006-06-26 | 2008-01-31 | Enanta Pharm Inc | QUINOXALINIL MACROCECLIC INHIBITORS OF SERINE PROTEASE VIRUS OF HEPATITIS C |
CN101674844A (en) * | 2006-08-04 | 2010-03-17 | 英安塔制药有限公司 | tetrazolyl macrocyclic hepatitis c serine protease inhibitors |
US7662779B2 (en) * | 2006-08-11 | 2010-02-16 | Enanta Pharmaceuticals, Inc. | Triazolyl macrocyclic hepatitis C serine protease inhibitors |
WO2008070733A2 (en) * | 2006-12-06 | 2008-06-12 | Phenomix Corporation | Macrocyclic hepatitis c serine protease inhibitors and uses therefor |
US20100081672A1 (en) * | 2006-12-07 | 2010-04-01 | Schering Corporation | Ph sensitive matrix formulation |
US20090005387A1 (en) * | 2007-06-26 | 2009-01-01 | Deqiang Niu | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors |
CA2708042A1 (en) * | 2007-12-05 | 2009-06-11 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl derivatives |
US8268777B2 (en) * | 2007-12-05 | 2012-09-18 | Enanta Pharmaceuticals, Inc. | Oximyl macrocyclic derivatives |
WO2009079353A1 (en) * | 2007-12-14 | 2009-06-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic hcv serine protease inhibitors |
AR070413A1 (en) * | 2008-02-04 | 2010-04-07 | Idenix Pharmaceuticals Inc | SERINA PROTEASA MACROCICLIC INHIBITORS |
MX2010010276A (en) * | 2008-03-20 | 2011-03-25 | Enanta Pharm Inc | Fluorinated macrocyclic compounds as hepatitis c virus inhibitors. |
EA201071034A1 (en) * | 2008-04-15 | 2011-06-30 | Интермьюн, Инк. | NEW MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATIONS |
US8211891B2 (en) * | 2008-04-30 | 2012-07-03 | Enanta Pharmaceuticals, Inc. | Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors |
US20090285773A1 (en) * | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
CN101580535B (en) * | 2008-05-16 | 2012-10-03 | 太景生物科技股份有限公司 | Hcv protease inhibitors |
US20100272674A1 (en) * | 2008-12-04 | 2010-10-28 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
CA2758072A1 (en) | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
WO2010138791A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
LT2477980T (en) * | 2009-09-15 | 2016-09-26 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
TW201116540A (en) * | 2009-10-01 | 2011-05-16 | Intermune Inc | Therapeutic antiviral peptides |
US20120276047A1 (en) | 2009-11-25 | 2012-11-01 | Rosenblum Stuart B | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
EP2516430B1 (en) | 2009-12-22 | 2014-11-05 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
US20110178107A1 (en) * | 2010-01-20 | 2011-07-21 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
AU2011224698A1 (en) | 2010-03-09 | 2012-11-01 | Merck Sharp & Dohme Corp. | Fused Tricyclic Silyl Compounds and methods of use thereof for the treatment of viral diseases |
CA2805440A1 (en) | 2010-07-26 | 2012-02-09 | Merck Sharp & Dohme Corp. | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
EP2621279B1 (en) | 2010-09-29 | 2018-04-04 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
TW201309690A (en) | 2011-02-10 | 2013-03-01 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
SG194485A1 (en) | 2011-04-13 | 2013-12-30 | Merck Sharp & Dohme | 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
US9156872B2 (en) | 2011-04-13 | 2015-10-13 | Merck Sharp & Dohme Corp. | 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
EP2755981A4 (en) | 2011-09-14 | 2015-03-25 | Merck Sharp & Dohme | Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
MX2015004411A (en) | 2012-10-08 | 2016-04-06 | Abbvie Inc | Compounds useful for making hcv protease inhibitors. |
WO2015065817A1 (en) | 2013-10-30 | 2015-05-07 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989004669A1 (en) | 1987-11-18 | 1989-06-01 | Chiron Corporation | Nanbv diagnostics and vaccines |
EP0381216A1 (en) | 1989-02-01 | 1990-08-08 | Asahi Glass Company Ltd. | Hydrochlorofluorocarbon azeotropic or azeotropic-like mixture |
US5712145A (en) | 1990-04-04 | 1998-01-27 | Chiron Corporation | Hepatitis C virus protease |
WO2000009543A2 (en) * | 1998-08-10 | 2000-02-24 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
WO2000009558A1 (en) * | 1998-08-10 | 2000-02-24 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptides |
WO2000059929A1 (en) * | 1999-04-06 | 2000-10-12 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
WO2001074768A2 (en) | 2000-04-03 | 2001-10-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
CA2268391A1 (en) | 1996-10-18 | 1998-04-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
ES2234144T3 (en) | 1997-08-11 | 2005-06-16 | Boehringer Ingelheim (Canada) Ltd. | ANALOGS OF INHIBITING PEPTIDES OF HEPATITIS C. |
US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
CA2405521C (en) | 2000-04-05 | 2010-06-29 | Schering Corporation | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties |
CN1432022A (en) | 2000-04-19 | 2003-07-23 | 先灵公司 | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties |
IL153670A0 (en) | 2000-07-21 | 2003-07-06 | Schering Corp | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
AR029851A1 (en) | 2000-07-21 | 2003-07-16 | Dendreon Corp | NEW PEPTIDES AS INHIBITORS OF NS3-SERINA PROTEASA DEL VIRUS DE HEPATITIS C |
AR034127A1 (en) | 2000-07-21 | 2004-02-04 | Schering Corp | IMIDAZOLIDINONES AS INHIBITORS OF NS3-SERINA PROTEASA OF THE HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITION, A METHOD FOR THEIR PREPARATION, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
JP2004504407A (en) | 2000-07-21 | 2004-02-12 | コルバス・インターナショナル・インコーポレイテッド | Novel peptide as NS3-serine protease inhibitor of hepatitis C virus |
KR20030091946A (en) | 2000-12-12 | 2003-12-03 | 쉐링 코포레이션 | Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus |
-
2004
- 2004-11-19 JP JP2006541606A patent/JP2007532479A/en active Pending
- 2004-11-19 WO PCT/US2004/039131 patent/WO2005051980A1/en active Application Filing
- 2004-11-19 CA CA002546290A patent/CA2546290A1/en not_active Abandoned
- 2004-11-19 US US10/993,394 patent/US7253160B2/en not_active Expired - Fee Related
- 2004-11-19 CN CNA2004800399478A patent/CN1902216A/en active Pending
- 2004-11-19 EP EP04811791A patent/EP1689770A1/en not_active Withdrawn
- 2004-11-19 MX MXPA06005683A patent/MXPA06005683A/en active IP Right Grant
-
2007
- 2007-06-27 US US11/769,455 patent/US7442695B2/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989004669A1 (en) | 1987-11-18 | 1989-06-01 | Chiron Corporation | Nanbv diagnostics and vaccines |
EP0381216A1 (en) | 1989-02-01 | 1990-08-08 | Asahi Glass Company Ltd. | Hydrochlorofluorocarbon azeotropic or azeotropic-like mixture |
US5712145A (en) | 1990-04-04 | 1998-01-27 | Chiron Corporation | Hepatitis C virus protease |
WO2000009543A2 (en) * | 1998-08-10 | 2000-02-24 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
WO2000009558A1 (en) * | 1998-08-10 | 2000-02-24 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptides |
WO2000059929A1 (en) * | 1999-04-06 | 2000-10-12 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
WO2001074768A2 (en) | 2000-04-03 | 2001-10-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
Cited By (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8314141B2 (en) | 1996-10-18 | 2012-11-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease |
US8710229B2 (en) | 2002-05-20 | 2014-04-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7915291B2 (en) | 2002-05-20 | 2011-03-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8299094B2 (en) | 2002-05-20 | 2012-10-30 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7449479B2 (en) | 2002-05-20 | 2008-11-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9636375B2 (en) | 2002-05-20 | 2017-05-02 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9227940B2 (en) | 2002-05-20 | 2016-01-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8507722B2 (en) | 2002-05-20 | 2013-08-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8889871B2 (en) | 2002-05-20 | 2014-11-18 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2006130666A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
WO2006130666A3 (en) * | 2005-06-02 | 2007-06-21 | Schering Corp | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2007019674A1 (en) | 2005-08-12 | 2007-02-22 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
EP2364984A1 (en) | 2005-08-26 | 2011-09-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
EP2366704A1 (en) | 2005-08-26 | 2011-09-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7935670B2 (en) | 2006-07-11 | 2011-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7897622B2 (en) | 2006-08-17 | 2011-03-01 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7906513B2 (en) * | 2007-04-26 | 2011-03-15 | Enanta Pharmaceuticals, Inc. | Hydrazide-containing hepatitis C serine protease inhibitors |
US8242140B2 (en) | 2007-08-03 | 2012-08-14 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
WO2009076173A2 (en) | 2007-12-05 | 2009-06-18 | Enanta Pharmaceuticals, Inc. | Fluorinated tripeptide hcv serine protease inhibitors |
WO2009076747A1 (en) | 2007-12-19 | 2009-06-25 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US8912182B2 (en) | 2007-12-19 | 2014-12-16 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US8541402B2 (en) | 2007-12-19 | 2013-09-24 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US8476257B2 (en) | 2007-12-19 | 2013-07-02 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US8741837B2 (en) | 2007-12-21 | 2014-06-03 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
EP2237666A1 (en) * | 2007-12-21 | 2010-10-13 | Avila Therapeutics, Inc. | Hcv protease inhibitors and uses thereof |
US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
US9694086B2 (en) | 2007-12-21 | 2017-07-04 | Celgene Car Llc | HCV protease inhibitors and uses thereof |
US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
KR20100131971A (en) * | 2007-12-21 | 2010-12-16 | 아빌라 테라퓨틱스, 인크. | Hcv protease inhibitors and uses thereof |
US8338606B2 (en) | 2007-12-21 | 2012-12-25 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
US9676785B2 (en) | 2007-12-21 | 2017-06-13 | Celgene Car Llc | HCV protease inhibitors and uses thereof |
US8778877B2 (en) | 2007-12-21 | 2014-07-15 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
EP2237666A4 (en) * | 2007-12-21 | 2012-05-16 | Avila Therapeutics Inc | Hcv protease inhibitors and uses thereof |
KR101683559B1 (en) | 2007-12-21 | 2016-12-08 | 셀진 아빌로믹스 리서치, 인코포레이티드 | HCV protease inhibitors and uses thereof |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8044023B2 (en) | 2008-05-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
US8357806B2 (en) | 2008-09-04 | 2013-01-22 | Bristol-Myers Squibb Company | Process for synthesizing substituted isoquinolines |
US8877929B2 (en) | 2008-09-04 | 2014-11-04 | Bristol-Myers Squibb Company | Process for synthesizing substituted isoquinolines |
US8642538B2 (en) | 2008-09-11 | 2014-02-04 | Abbvie, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
US8420596B2 (en) | 2008-09-11 | 2013-04-16 | Abbott Laboratories | Macrocyclic hepatitis C serine protease inhibitors |
US9309279B2 (en) | 2008-09-11 | 2016-04-12 | Abbvie Inc. | Macrocyclic hepatitis C serine protease inhibitors |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2010080874A1 (en) | 2009-01-07 | 2010-07-15 | Scynexis, Inc. | Cyclosporine derivative for use in the treatment of hcv and hiv infection |
WO2010132163A1 (en) | 2009-05-13 | 2010-11-18 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis c virus inhibitors |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
EP3020723A1 (en) | 2010-09-21 | 2016-05-18 | Enanta Pharmaceuticals, Inc. | Macrocyclic proline derived hcv serine protease inhibitors |
US8951964B2 (en) | 2010-12-30 | 2015-02-10 | Abbvie Inc. | Phenanthridine macrocyclic hepatitis C serine protease inhibitors |
US8937041B2 (en) | 2010-12-30 | 2015-01-20 | Abbvie, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
US9527885B2 (en) | 2011-05-05 | 2016-12-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201541B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9499550B2 (en) | 2012-10-19 | 2016-11-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9580463B2 (en) | 2013-03-07 | 2017-02-28 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9744170B2 (en) | 2014-01-03 | 2017-08-29 | Abbvie Inc. | Solid antiviral dosage forms |
US10105365B2 (en) | 2014-01-03 | 2018-10-23 | Abbvie Inc. | Solid antiviral dosage forms |
US9333204B2 (en) | 2014-01-03 | 2016-05-10 | Abbvie Inc. | Solid antiviral dosage forms |
Also Published As
Publication number | Publication date |
---|---|
US20070258947A1 (en) | 2007-11-08 |
CA2546290A1 (en) | 2005-06-09 |
EP1689770A1 (en) | 2006-08-16 |
WO2005051980A8 (en) | 2006-09-08 |
US7253160B2 (en) | 2007-08-07 |
US20050164921A1 (en) | 2005-07-28 |
CN1902216A (en) | 2007-01-24 |
MXPA06005683A (en) | 2006-12-14 |
JP2007532479A (en) | 2007-11-15 |
US7442695B2 (en) | 2008-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7442695B2 (en) | Depeptidized inhibitors of hepatitis C virus NS3 protease | |
EP1773868B1 (en) | Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease | |
EP1737821B1 (en) | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease | |
EP1737881B1 (en) | Novel compounds as inhibitors of hepatitis c virus ns3 serine protease | |
EP1797111B1 (en) | Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease | |
US7485625B2 (en) | Inhibitors of hepatitis C virus NS3/NS4a serine protease | |
EP1664092B1 (en) | Macrocyclic inhibitors of hepatitis c virus ns3 serine protease | |
EP1730142B1 (en) | Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus | |
EP2134739B1 (en) | Sulfur compounds as inhiibitors of hepatitis c virus ns3 serine protease | |
EP1748983A2 (en) | Compounds as inhibitors of hepatitis c virus ns3 serine protease | |
WO2005107745A1 (en) | An inhibitor of hepatitis c | |
EP1730165A1 (en) | Inhibitors of hepatitis c virus ns3 protease | |
WO2008118332A2 (en) | Hydrazido-peptides as inhibitors of hcv ns3-protease | |
EP1742914A1 (en) | Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2546290 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006541606 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/005683 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004811791 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200480039947.8 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004811791 Country of ref document: EP |